CARVEDILOL Drug Interactions
Also known as: Carvedilol
Carvedilol is a medication known as an alpha and beta blocker. It is prescribed to treat conditions such as high blood pressure, chronic heart failure, and to improve outcomes after a heart attack. Carvedilol works by relaxing blood vessels and slowing the heart rate, which helps the heart pump blood more easily and efficiently.CARVEDILOL has 8 documented drug interactions in our database, including 0 contraindicated, 3 major, 3 moderate, and 2 minor interactions.
0
Contraindicated
3
Major
3
Moderate
2
Minor
Combining metoprolol and carvedilol, both beta-blockers, can lead to an additive effect, significantly increasing the risk of bradycardia, hypotension, and heart failure exacerbation. This combination is generally not recommended due to the heightened risk of adverse cardiovascular events.
Mechanism
Both metoprolol and carvedilol exert their primary therapeutic effects by blocking beta-adrenergic receptors, leading to decreased heart rate, myocardial contractility, and blood pressure. Their co-administration results in an enhanced pharmacodynamic effect, increasing the likelihood of profound beta-blockade.
Clinical Management
This combination should generally be avoided. If a patient requires more intensive beta-blockade, consider optimizing the dose of a single beta-blocker or exploring alternative drug classes. If co-administration is deemed absolutely necessary, close monitoring for bradycardia, hypotension, and signs of heart failure is crucial, and dosage adjustments of both agents may be required.
Fluoxetine is a potent inhibitor of CYP2D6, which is a primary enzyme responsible for the metabolism of carvedilol. This inhibition can lead to significantly increased plasma concentrations of carvedilol, raising the risk of adverse effects such as severe bradycardia, hypotension, and heart block.
Mechanism
Fluoxetine inhibits the cytochrome P450 2D6 (CYP2D6) enzyme. Carvedilol is metabolized by CYP2D6, so fluoxetine reduces carvedilol's metabolism, increasing its systemic exposure and pharmacodynamic effects.
Clinical Management
Concomitant use should generally be avoided or managed with extreme caution. If co-administration is necessary, carvedilol dosage should be significantly reduced and the patient closely monitored for signs of bradycardia, hypotension, and heart block. Consider using an alternative antidepressant with minimal CYP22D6 inhibition (e.g., sertraline, escitalopram) or a beta-blocker not primarily metabolized by CYP2D6 (e.g., atenolol, bisoprolol).
Concurrent use of carvedilol and paroxetine can lead to significantly increased plasma concentrations of carvedilol. This elevation in carvedilol levels can result in enhanced beta-blocking effects, potentially causing severe bradycardia, hypotension, or heart block.
Mechanism
Paroxetine is a potent inhibitor of the cytochrome P450 2D6 (CYP2D6) enzyme. Carvedilol is primarily metabolized by CYP2D6, so paroxetine inhibits its metabolism, leading to reduced clearance and increased systemic exposure of carvedilol.
Clinical Management
Avoid co-administration if possible. If concomitant use is unavoidable, a significant reduction in carvedilol dosage (e.g., by 50% or more) should be considered, and the patient must be closely monitored for signs of bradycardia, hypotension, and heart block, especially during initiation or dose changes of paroxetine. Consider using an alternative antidepressant with minimal CYP2D6 inhibition (e.g., sertraline, escitalopram) or an alternative beta-blocker not primarily metabolized by CYP2D6 (e.g., atenolol).
Fluoxetine inhibits CYP2D6, increasing carvedilol plasma levels and potentially causing excessive beta-blockade.
Mechanism
Carvedilol is primarily metabolized by CYP2D6. Fluoxetine's CYP2D6 inhibition increases carvedilol AUC by up to 77%.
Clinical Management
Monitor for signs of excessive beta-blockade (bradycardia, hypotension). Consider dose reduction of carvedilol.
Citalopram is a moderate inhibitor of CYP2D6, which is the primary enzyme responsible for the metabolism of carvedilol. This interaction can lead to increased plasma concentrations of carvedilol, potentially enhancing its beta-blocking effects and increasing the risk of bradycardia, hypotension, or heart block.
Mechanism
Citalopram inhibits the cytochrome P450 2D6 (CYP2D6) enzyme. Carvedilol is extensively metabolized by CYP2D6, so inhibition of this enzyme by citalopram reduces carvedilol clearance, leading to elevated systemic exposure.
Clinical Management
Monitor patients closely for signs and symptoms of increased beta-blockade, such as bradycardia, hypotension, dizziness, or fatigue, when citalopram is initiated or its dose is changed. A carvedilol dose reduction may be necessary, or consider using an alternative antidepressant with minimal CYP2D6 inhibitory activity, such as escitalopram or sertraline.
Coadministration of carvedilol and fluvoxamine may lead to increased plasma concentrations of carvedilol, potentially enhancing its beta-blocking effects. This can result in symptoms such as bradycardia, hypotension, and dizziness, particularly in susceptible patients.
Mechanism
Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19. While carvedilol is primarily metabolized by CYP2D6, it also undergoes metabolism by CYP2C9, CYP1A2, and CYP3A4. Inhibition of CYP1A2 by fluvoxamine could reduce the clearance of carvedilol, leading to elevated systemic exposure.
Clinical Management
Monitor patients for signs and symptoms of increased beta-blockade, including bradycardia, hypotension, and dizziness, especially when fluvoxamine is initiated or its dose is changed. A carvedilol dose reduction may be necessary if adverse effects occur. Consider using alternative antidepressants with less CYP1A2 inhibitory activity if close monitoring is not feasible.
Sertraline is a weak inhibitor of CYP2D6, the primary enzyme metabolizing carvedilol. While a theoretical increase in carvedilol plasma concentrations is possible, it is generally not considered clinically significant for most patients.
Mechanism
Carvedilol is primarily metabolized by CYP2D6. Sertraline is a weak inhibitor of CYP2D6, which could potentially reduce the metabolism of carvedilol and increase its systemic exposure.
Clinical Management
Routine co-administration of carvedilol and sertraline typically does not require specific dose adjustments or enhanced monitoring. However, clinicians should be aware of the potential for increased carvedilol effects (e.g., bradycardia, hypotension) in sensitive individuals, especially if sertraline dosage is high or if other CYP2D6 inhibitors are present.
Escitalopram is a weak inhibitor of CYP2D6, the enzyme responsible for the metabolism of carvedilol. While a theoretical increase in carvedilol levels is possible, it is generally not considered clinically significant for most patients.
Mechanism
Carvedilol is primarily metabolized by CYP2D6. Escitalopram is a weak inhibitor of CYP2D6, which could theoretically reduce the metabolism of carvedilol, leading to increased plasma concentrations.
Clinical Management
Due to escitalopram's minimal CYP2D6 inhibition, significant dose adjustments for carvedilol are usually not required. Monitor patients for signs of increased beta-blockade, such as bradycardia or hypotension, especially if they are sensitive to carvedilol or have underlying cardiac conditions.
For complete prescribing information:
View full CARVEDILOL monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.